Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Delcath Systems Inc's Business Segments
Delcath Systems Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
HEPZATO KIT
Total Revenue
$ 29
Regions Reported
1
Revenue Share by Reportable Segment - FY
- HEPZATO KIT0%
- CHEMOSAT12.8%
- Non-US12.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| HEPZATO KIT | $ 50 | - |
| CHEMOSAT | $ 4 | 12.8% |
| Non-US | $ 4 | 12.8% |
Revenue Share by Region - FY
- Non-US7.2%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 2 | 7.2% |
Revenue by Product & Service Category - FY
- HEPZATO KIT95.8%
- CHEMOSAT7.2%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| HEPZATO KIT | $ 23 | 95.8% |
| CHEMOSAT | $ 2 | 7.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- HEPZATO KIT0%
- CHEMOSAT12.8%
- Non-US12.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| HEPZATO KIT | $ 50 | - |
| CHEMOSAT | $ 4 | 12.8% |
| Non-US | $ 4 | 12.8% |
Description of Delcath Systems Inc
Delcath Systems Inc. is a medical technology company that specializes in the development and commercialization of a unique therapeutic system called the Percutaneous Hepatic Perfusion (PHP) system. The company's primary focus is on the treatment of liver cancer and other liver diseases.
The PHP system is designed to isolate and deliver high-dose chemotherapy directly to the liver, while minimizing the exposure of healthy tissues and organs. This targeted approach allows for the administration of significantly higher doses of chemotherapy drugs, which can increase the effectiveness of treatment while reducing systemic side effects.
The PHP system consists of several components, including a catheter-based infusion system, a dual-balloon catheter, and a specialized filtration system. The procedure begins with the placement of a catheter in the femoral artery, which is then guided to the liver. Once in position, the dual-balloon catheter is inflated to isolate the liver so that the high-dose chemotherapy can be delivered directly to the liver.
During treatment, the specialized filtration system works to continually remove the drug from the blood as it circulates through the liver, reducing the risk of systemic toxicity. The filtered blood is then returned to the body via a catheter in the femoral vein.
Delcath Systems has conducted extensive clinical trials to assess the safety and efficacy of the PHP system. The results have shown promising outcomes, with significant tumor shrinkage and improved overall survival rates observed in patients with liver cancer.
In addition to liver cancer, Delcath Systems is also exploring the potential of the PHP system as a treatment option for other liver diseases, such as hepatocellular carcinoma and cholangiocarcinoma. The company is actively engaged in research and development activities to further expand the applications of the technology.
Delcath Systems has also established partnerships with various medical centers and hospitals to facilitate the adoption and integration of the PHP system into clinical practice. This collaborative approach enables the company to gather real-world data and feedback from physicians and patients, which is crucial for ongoing product improvement and refinement.
In terms of regulatory approvals and commercialization, Delcath Systems has received CE Mark certification in Europe for the PHP system, allowing for sales and marketing in the European Union. The company is also pursuing regulatory clearance from the U.S. Food and Drug Administration (FDA) to make the PHP system available in the United States.
Overall, Delcath Systems Inc. is a medical technology company that is at the forefront of developing innovative solutions for the treatment of liver cancer and other liver diseases. Through its PHP system, the company aims to improve patient outcomes by delivering targeted, high-dose chemotherapy directly to the liver, while minimizing the exposure to healthy tissues and organs.
The PHP system is designed to isolate and deliver high-dose chemotherapy directly to the liver, while minimizing the exposure of healthy tissues and organs. This targeted approach allows for the administration of significantly higher doses of chemotherapy drugs, which can increase the effectiveness of treatment while reducing systemic side effects.
The PHP system consists of several components, including a catheter-based infusion system, a dual-balloon catheter, and a specialized filtration system. The procedure begins with the placement of a catheter in the femoral artery, which is then guided to the liver. Once in position, the dual-balloon catheter is inflated to isolate the liver so that the high-dose chemotherapy can be delivered directly to the liver.
During treatment, the specialized filtration system works to continually remove the drug from the blood as it circulates through the liver, reducing the risk of systemic toxicity. The filtered blood is then returned to the body via a catheter in the femoral vein.
Delcath Systems has conducted extensive clinical trials to assess the safety and efficacy of the PHP system. The results have shown promising outcomes, with significant tumor shrinkage and improved overall survival rates observed in patients with liver cancer.
In addition to liver cancer, Delcath Systems is also exploring the potential of the PHP system as a treatment option for other liver diseases, such as hepatocellular carcinoma and cholangiocarcinoma. The company is actively engaged in research and development activities to further expand the applications of the technology.
Delcath Systems has also established partnerships with various medical centers and hospitals to facilitate the adoption and integration of the PHP system into clinical practice. This collaborative approach enables the company to gather real-world data and feedback from physicians and patients, which is crucial for ongoing product improvement and refinement.
In terms of regulatory approvals and commercialization, Delcath Systems has received CE Mark certification in Europe for the PHP system, allowing for sales and marketing in the European Union. The company is also pursuing regulatory clearance from the U.S. Food and Drug Administration (FDA) to make the PHP system available in the United States.
Overall, Delcath Systems Inc. is a medical technology company that is at the forefront of developing innovative solutions for the treatment of liver cancer and other liver diseases. Through its PHP system, the company aims to improve patient outcomes by delivering targeted, high-dose chemotherapy directly to the liver, while minimizing the exposure to healthy tissues and organs.
Delcath Systems Inc. is a biotech company focused on the development of unique therapies aimed at delivering drugs directly to tumors while minimizing systemic exposure to those drugs. Their primary focus is on the treatment of cancer, particularly liver cancer and metastatic disease. Below are the extensive segments, products, and services offered by Delcath Systems Inc.:
Segments
1. Oncology: This segment is dedicated to developing and innovating treatment options for cancer patients, particularly those with targeted and localized therapies that aim to improve efficacy while reducing side effects associated with systemic chemotherapy.
2. Medical Devices: Delcath is heavily involved in the creation of specialized medical devices designed to facilitate their innovative treatment delivery systems. This segment focuses on operational aspects including manufacturing, compliance, and distribution of the medical devices used in their therapies.
3. Pharmaceuticals: In conjunction with their medical devices, Delcath formulates pharmaceutical products specifically designed for their drug delivery system. This includes both established chemotherapeutic agents and new drug formulations intended for localized administration.
4. Clinical Development: Delcath is actively engaged in ongoing clinical trials and studies to test the safety and efficacy of their products. This segment encompasses research and development activities, regulatory compliance, and collaborations with clinical institutions.
Products
1. Hepatic Chemoembolization: This is the cornerstone of Delcath’s treatment paradigm, aimed at delivering high doses of chemotherapy directly to the liver tumors through a catheter, significantly intensifying the drug’s effect while reducing systemic toxicity.
2. Melphalan/HDS (High Dose System): One of Delcath’s flagged products is the high-dose Melphalan delivery system, a form of chemotherapy specifically used for patients with unresectable liver cancer. This system focuses on maximizing local drug concentrations while minimizing exposure to the rest of the body.
3. HDS Catheter System: This device is integral to delivering localized chemotherapy treatments. Designed for the precise targeting of tumors, this catheter reduces the side effects typically associated with systemic delivery of chemotherapy drugs.
4. Inferior Vena Cava (IVC) Filter: Delcath offers an IVC filter to prevent blood clots during procedures involving high doses of chemotherapy, ensuring safety during the administration of their treatments.
5. Therapeutic Imaging Technology: To enhance the delivery and effectiveness of therapies, Delcath has developed imaging technologies that facilitate the visualization of tumor sites and the monitoring of treatment efficacy, allowing for better treatment planning and execution.
Services
1. Clinical Trials and Studies: Delcath sponsors and conducts clinical trials to gather data on the efficacy and safety of their products. They offer services in patient recruitment, trial management, and regulatory submission processes to ensure world-class clinical research standards.
2. Training and Support: Delcath provides extensive training for healthcare providers on the effective use of their medical devices and treatment protocols. This encompasses workshops, seminars, and on-site training programs.
3. Regulatory Affairs and Compliance: Delcath offers guidance to ensure compliance with regulatory bodies, including the preparation of submissions for new treatments and devices, adherence to clinical trial regulations, and post-market surveillance of products.
4. Patient Education and Support Programs: Delcath is committed to providing comprehensive education for patients undergoing treatment with their therapies. This includes safety information, treatment protocols, and ongoing support through their patient services program.
5. Partnerships and Collaborations: Delcath actively engages in partnerships with hospitals, cancer treatment centers, and research institutions to enhance the reach and effectiveness of their products. They collaborate in clinical studies and share research findings to improve cancer treatment outcomes.
Through these segments, products, and services, Delcath Systems Inc. aims to provide innovative, targeted therapies for cancer patients, leveraging cutting-edge technology to improve treatment efficacy and patient quality of life.
Segments
1. Oncology: This segment is dedicated to developing and innovating treatment options for cancer patients, particularly those with targeted and localized therapies that aim to improve efficacy while reducing side effects associated with systemic chemotherapy.
2. Medical Devices: Delcath is heavily involved in the creation of specialized medical devices designed to facilitate their innovative treatment delivery systems. This segment focuses on operational aspects including manufacturing, compliance, and distribution of the medical devices used in their therapies.
3. Pharmaceuticals: In conjunction with their medical devices, Delcath formulates pharmaceutical products specifically designed for their drug delivery system. This includes both established chemotherapeutic agents and new drug formulations intended for localized administration.
4. Clinical Development: Delcath is actively engaged in ongoing clinical trials and studies to test the safety and efficacy of their products. This segment encompasses research and development activities, regulatory compliance, and collaborations with clinical institutions.
Products
1. Hepatic Chemoembolization: This is the cornerstone of Delcath’s treatment paradigm, aimed at delivering high doses of chemotherapy directly to the liver tumors through a catheter, significantly intensifying the drug’s effect while reducing systemic toxicity.
2. Melphalan/HDS (High Dose System): One of Delcath’s flagged products is the high-dose Melphalan delivery system, a form of chemotherapy specifically used for patients with unresectable liver cancer. This system focuses on maximizing local drug concentrations while minimizing exposure to the rest of the body.
3. HDS Catheter System: This device is integral to delivering localized chemotherapy treatments. Designed for the precise targeting of tumors, this catheter reduces the side effects typically associated with systemic delivery of chemotherapy drugs.
4. Inferior Vena Cava (IVC) Filter: Delcath offers an IVC filter to prevent blood clots during procedures involving high doses of chemotherapy, ensuring safety during the administration of their treatments.
5. Therapeutic Imaging Technology: To enhance the delivery and effectiveness of therapies, Delcath has developed imaging technologies that facilitate the visualization of tumor sites and the monitoring of treatment efficacy, allowing for better treatment planning and execution.
Services
1. Clinical Trials and Studies: Delcath sponsors and conducts clinical trials to gather data on the efficacy and safety of their products. They offer services in patient recruitment, trial management, and regulatory submission processes to ensure world-class clinical research standards.
2. Training and Support: Delcath provides extensive training for healthcare providers on the effective use of their medical devices and treatment protocols. This encompasses workshops, seminars, and on-site training programs.
3. Regulatory Affairs and Compliance: Delcath offers guidance to ensure compliance with regulatory bodies, including the preparation of submissions for new treatments and devices, adherence to clinical trial regulations, and post-market surveillance of products.
4. Patient Education and Support Programs: Delcath is committed to providing comprehensive education for patients undergoing treatment with their therapies. This includes safety information, treatment protocols, and ongoing support through their patient services program.
5. Partnerships and Collaborations: Delcath actively engages in partnerships with hospitals, cancer treatment centers, and research institutions to enhance the reach and effectiveness of their products. They collaborate in clinical studies and share research findings to improve cancer treatment outcomes.
Through these segments, products, and services, Delcath Systems Inc. aims to provide innovative, targeted therapies for cancer patients, leveraging cutting-edge technology to improve treatment efficacy and patient quality of life.